<DOC>
	<DOCNO>NCT02879448</DOCNO>
	<brief_summary>The Amulet™ device evaluate safety efficacy demonstrate performance non-inferior commercially available WATCHMAN® leave atrial appendage closure device patient non-valvular atrial fibrillation . Patients eligible trial randomize receive either Amulet device WATCHMAN device follow 5 year device implant .</brief_summary>
	<brief_title>AMPLATZER™ Amulet™ LAA Occluder Trial</brief_title>
	<detailed_description>The Amulet IDE trial prospective , randomize , multi-center active control worldwide trial , design evaluate safety effectiveness AMPLATZER™ Amulet™ Left Atrial Appendage Occluder . Subjects randomize 1:1 ratio Amulet LAA occlusion device ( treatment ) Boston Scientific WATCHMAN® LAA closure device ( Control ) . The trial conduct 150 site worldwide . All enrolled subject follow protocol-required test assessment schedule follow-up visit .</detailed_description>
	<criteria>1 . 18 year age old 2 . Documented paroxysmal , persistent , permanent nonvalvular atrial fibrillation ( AF ) patient diagnose rheumatic mitral valvular heart disease 3 . At high risk stroke systemic embolism define CHADS2 score &gt; 2 CHA2DS2VASc score &gt; 3 4 . Has appropriate rationale seek alternative warfarin anticoagulation medication 5 . Deemed investigator suitable short term warfarin therapy deem unable take long term oral anticoagulation follow conclusion share decision making ( see inclusion criterion # 6 ) 6 . Deemed suitable LAA closure multidisciplinary team medical professional ( include independent noninterventional physician ) involve formal share decision make process , use evidencebased decision tool oral anticoagulation ( final determination must document subject 's medical record ) 7 . Able comply require medication regimen postdevice implant 8 . Able understand willing provide write informed consent participate trial 9 . Able willing return require followup visit examination 1 . Requires longterm oral anticoagulation therapy condition atrial fibrillation 2 . Contraindicated allergic aspirin , clopidogrel , warfarin use 3 . Indicated chronic P2Y12 platelet therapy inhibitor 4 . Has undergone atrial septal defect ( ASD ) repair ASD closure device implant 5 . Has undergone patent foramen ovale ( PFO ) repair PFO closure device implant 6 . Implanted mechanical valve prosthesis 7 . Has customary contraindication percutaneous catheterization procedure ( e.g . subject small accommodate transesophageal echocardiogram ( TEE/TOE ) probe require catheter , subject active infection bleed disorder ) 8 . Stroke transient ischemic attack ( TIA ) within 90 day prior randomization implant procedure ( applicable ) 9 . Underwent cardiac noncardiac intervention surgery within 30 day prior randomization , intervention surgery plan within 60 day implant procedure 10 . Myocardial infarction ( MI ) within 90 day prior randomization 11 . New York Heart Association Class IV Congestive Heart Failure 12 . Left ventricular ejection Fraction ( LVEF ) &lt; 30 % 13 . Symptomatic carotid artery disease ( define &gt; 50 % stenosis symptoms ipsilateral transient visual TIA evidence amaurosis fugax , ipsilateral hemispheric TIAs ipsilateral stroke ) ; subject history carotid stent endarterectomy subject eligible &lt; 50 % stenosis 14 . Reversible cause AF ( i.e . secondary thyroid disorder , acute alcohol intoxication , trauma , recent major surgical procedure ) 15 . History idiopathic recurrent venous thromboembolism 16 . Left atrial appendage obliterate surgically ligate 17 . Resting heart rate &gt; 110 bpm 18 . Thrombocytopenia ( define &lt; 70,000 platelets/mm3 ) anemia hemoglobin concentration &lt; 10 g/dl ( i.e . anemia determine investigator would require transfusion ) 19 . Hypersensitivity portion device material individual component either Amulet Boston Scientific LAA closure device ( e.g . nickel allergy ) 20 . Actively enrol plan enroll concurrent clinical study active treatment arm may confound result trial 21 . Subject pregnant pregnancy plan course investigation 22 . Active endocarditis infection produce bacteremia 23 . Subject known malignancy illness life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Left Atrial Appendage</keyword>
</DOC>